Duality DB-1324 ADC FDA IND Approval Advances GSK Partnership
Duality Biotherapeutics, Inc. (HKG: 9606) announced that its Investigational New Drug (IND) application for DB-1324,...
Duality Biotherapeutics, Inc. (HKG: 9606) announced that its Investigational New Drug (IND) application for DB-1324,...
Duality Biotherapeutics, Inc. (DualityBio, HKG: 9606) announced that its co‑developed EGFR/HER3 bispecific antibody‑drug conjugate (ADC),...
Hong Kong‑listed Duality Biologics (DoalityBio, HKG: 9606) announced that the first patient has been dosed...
China‑based Duality Biotherapeutics, Inc. (HKG: 9606) announced that its Phase III study of the HER2‑targeting antibody‑drug...
Duality Biologics (HKG: 9606) announced that the US Food and Drug Administration (FDA) has granted...
Duality Biologics (HKG: 9606), a developer of antibody conjugate drugs (ADCs) operating in the United...
China-based Duality Biotherapeutics, Inc. (HKG: 9606) successfully debuted in Hong Kong after completing an initial...